Annual revenue rose from KRW 27.8 billion in 2022 to KRW 36.3 billion in 2023 (up 30.5%), KRW 37.9 billion in 2024 (up 4.3%) and KRW 43.2 billion in 2025 (up 14.0%). Revenue has grown for three straight years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.
Pharmaceutical sales, which rose about 29% in 2025, were the core of this growth and outpaced total revenue.
Operating profit moved from an operating loss of KRW 4.06 billion in 2022 (margin of -14.6%) to operating profit of KRW 965 million in 2023 (2.7%), back to an operating loss of KRW 70.55 million in 2024 (-0.2%), and then to operating profit of KRW 719 million in 2025 (1.7%).
Margins stayed in a narrow band even as revenue grew. Net loss attributable to controlling shareholders was KRW 42.1 billion in 2022, a profit of KRW 13.9 billion in 2023, a loss of KRW 26.3 billion in 2024 and a loss of KRW 11.5 billion in 2025, a narrower loss.
Net loss including non-controlling interests was KRW 26.5 billion in 2024 and KRW 11.4 billion in 2025, a different figure from the controlling-shareholder measure. The 2024 net loss was far larger than the operating loss, so non-operating items and tax lines in the notes to the annual report are worth checking.
The debt-to-equity ratio rose to 84.7% in 2024 and fell to 44.0% in 2025, when total equity was KRW 108.8 billion and total liabilities were KRW 47.8 billion. Operating cash flow turned positive in 2024 (KRW 1.22 billion) and 2025 (KRW 1.67 billion) after negative figures in 2022 and 2023.
On a quarterly basis, Q3 2025 revenue was KRW 9.82 billion with an operating loss of KRW 8.66 million and a controlling-shareholder net loss of KRW 4.88 billion. Q4 2025 revenue rose 35.6% to KRW 13.3 billion, with operating profit of KRW 2.63 billion and a controlling-shareholder net profit of KRW 9.85 billion.
Q1 2026 revenue fell 27.2% to KRW 9.7 billion and the company posted an operating loss of KRW 1.43 billion, while press reports put pharma sales at KRW 7.4 billion, or 76.5%, of that quarter. Q2 2026 revenue jumped 198.3% to KRW 28.9 billion and the operating loss narrowed to KRW 806 million.
Q3 2026 revenue of KRW 27.5 billion was up 180.3% year on year, but the operating loss widened to KRW 3.03 billion. Controlling-shareholder net losses over the last four quarters total KRW 17.4 billion.
How much the expanded consolidation scope contributed to the 2026 revenue jump should be checked in the annual report's consolidation notes.